Stacey Adam, PhD

Dr. Stacey Adam is a Vice President at the FNIH, leading many public-private partnerships, such as Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV); the Biomarkers Consortium (Cancer and Metabolic Disorders Steering Committees) and their projects; Accelerating Medicines Partnerships (AMPs)-Common Metabolic Diseases, Heart Failure, and Parkinson’s Disease, Partnership for Accelerating Cancer Therapies (PACT); and the Lung Master protocol (Lung-MAP) clinical trial.

Prior to FNIH, Dr. Adam was a Manager at Deloitte Consulting in the Federal Life Sciences and Healthcare Strategy practice where she supported many federal and non-profit client projects. Before Deloitte, Dr. Adam conducted her postdoctoral fellowship at Stanford University School of Medicine, where she was both an NIH and American Cancer Society supported fellow, and she earned her Ph.D. in Pharmacology with a Certificate in Mammalian Toxicology from Duke University.